werewolftx.com (HOWL): Long-Term Debt to Capital Ratio

Werewolf Therapeutics Inc. - graphic logo of issuer HOWL

Werewolf Therapeutics (HOWL) monetizes innovative cytokine developments through partnerships, targeting an undersaturated immuno-oncology market with massive demand. The ratio of long-term debt to equity visualizes financial stability under this approach, where 0.00 serves as the final level marker. Strong management of the PREDATOR platform ensures R&D transparency, although the model is susceptible to high cash burn risks.

HOWL - Werewolf Therapeutics Inc. Long-Term Debt to Equity over the range 07/04/2022 - 10/28/2026

Werewolf Therapeutics Inc. (HOWL) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Price Werewolf|HOWL - Price Target Chart
- market capitalization data:
Market Capitalization Werewolf Therapeutics, Inc.|HOWL - Enterprise Value
- book capitalization data:
Accounting Value per Share Werewolf Therapeutics|HOWL - Company Book Value|Market-to-Book Ratio werewolftx.com|HOWL - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Werewolf Therapeutics|HOWL - Long-Term Debt to Equity|Current Liabilities to Capital Werewolf|HOWL - Company Aggregate Debts|Debt to Net Assets Werewolf Therapeutics, Inc.|HOWL - Company Long-Term Liabilities|Short-Term Debt Werewolf Therapeutics
Fundamental company valuation:HOWL werewolftx.com
Brand item of Werewolf Therapeutics, Inc.

Werewolf Therapeutics (HOWL) is scaling the development of its Indukine platform to combat tumors. An analysis of long-term debt financial leverage allows for an assessment of the company's reliance on external borrowings relative to its equity. This metric compares liabilities with a maturity of more than one year against net assets. A low ratio confirms the funding autonomy of WTX-124 clinical trials, ensuring business stability during its expansion into the immuno-oncology niche.

Who Werewolf Therapeutics competes with

Long-Term Liabilities to Capital IBRX|Long-Term Debt to Equity Immunocore PLC IMCR|Long-Term Debt to Capital Ratio Janux Corp (JANX)|Arcus Biosciences, Inc. - Long-Term Debt to Capital|zymeworks.com - Long-Term Debt to Equity Ratio|TNGX (Tango Therapeutics, Inc.) - Long-Term Debt to Equity|IOVA: Long-Term Liabilities to Capital|Immatics Corp (IMTX) - Long-Term Debt to Equity|XNCR (Xencor Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity CMPX (Compass Therapeutics)|Long-Term Liabilities to Capital replimune.com|LYEL: Long-Term Debt to Capital|Long-Term Indebtedness to Equity Innate Pharma SA IPHA|PYXS: Long-Term Debt to Equity Ratio|CGEN - Long-Term Liabilities to Capital|Long-Term Debt to Equity Ratio IO Biotech, Inc. (IOBT)|STRO - Long-Term Debt to Capital Coefficient|MiNK Therapeutics - Long-Term Debt to Capital|IMMX (Immix Biopharma) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ALXO|Long-Term Debt to Equity Ratio CUE|Long-Term Debt to Equity PDSB (PDS Biotechnology)|Long-Term Debt to Equity Ratio sonnetbio.com SONN|Long-Term Debt to Equity Ratio MAIA (MAIA Biotechnology, Inc.)|Liminatus Pharma Inc. - Long-Term Debt to Capital|Lava Tx (LVTX) - Long-Term Debt to Equity|NXTC: Long-Term Debt to Capital Ratio|Long-Term Debt to Equity LPTX|Long-Term Liabilities to Capital Intensity Therapeutics, Inc.|Sensei Biotherapeutics Inc - Long-Term Debt to Equity Ratio|Long-Term Indebtedness to Equity Theriva Biologics Inc (TOVX)|Long-Term Debt to Equity Ratio Gritstone bio, Inc.|Long-Term Loans to Capital Ratio Kineta Corp (KA)|Long-Term Debt to Capital NexImmune, Inc.|Long-Term Debt to Capital Coefficient Turnstone Biologics Corp TSBX|VCNX (Vaccinex) - Long-Term Debt to Capital|HARP: Long-Term Liabilities to Capital